Hello, and welcome to the final Kable of a busy week and an even busier month. On this last day in April, life sciences news shows no signs of slowing down. Big Pharma is going full steam ahead with its restructuring plans, with companies streamlining their efforts by dumping some R&D projects and investing in more commercially-viable ones. Today’s Kabl…
💉 Winner in sight for RSV race; AstraZeneca dumps $855 million rare disease drug; Eli Lilly sees success in obesity drug trial
#329 | Oceans get hotter; Big Pharma’s R&D pipeline gets lighter; Mammalian genomes remain unchanged
